Development of monetite/phosphorylated chitosan composite bone cement.

Orthopedic cements are widely used for bone repair, but their long-term performance and biocompatibility remain areas of active investigation. Existing cements often face challenges such as poor mechanical strength and limited biodegradability. Researchers have explored various composite materials to address these issues. Monetite, a form of dicalcium phosphate, has shown promise due to its osteoconductive properties. However, its setting time and mechanical performance need improvement. Chitosan, a natural polymer, has been modified to enhance its compatibility with inorganic phases. Prior research has shown that phosphorylated chitosan can improve the handling and mechanical properties of cements. That uncertainty drove the current investigation into a monetite/phosphorylated chitosan composite. No prior work had resolved the optimal ratio for such a combination. This gap motivated the study of how p-chitosan affects monetite cement properties. The researchers aimed to determine whether this composite could offer a viable alternative to conventional bone cements.

The study aimed to develop a novel composite cement using monetite and phosphorylated chitosan. The researchers wanted to assess how p-chitosan affects the mechanical and biological properties of the cement. They focused on optimizing the p-chitosan content to improve the cement's performance. The goal was to create a material with good injectability, washout resistance, and compressive strength. The team also examined the cytocompatibility of the composite. They compared the new cement to traditional materials like hydroxyapatite. The motivation was to find a biodegradable alternative that supports bone regeneration. The researchers proposed that the right combination of p-chitosan and monetite could enhance cement functionality.

The researchers prepared cement pastes by mixing monetite with phosphorylated chitosan powders. They varied the p-chitosan content to determine the optimal ratio. The pastes were tested for injectability and washout resistance. Mechanical properties were measured using compression tests. The setting time of the cement was recorded under controlled conditions. The team used preosteoblast cells to evaluate cytocompatibility. Cell proliferation was assessed using standard in vitro techniques. The results were compared to those of hydroxyapatite and untreated chitosan composites.

The composite cement with 5 wt % p-chitosan had a significantly shorter setting time than pure monetite. The compressive strength nearly doubled from 11.09 MPa to 23.43 MPa at this ratio. Higher p-chitosan content or untreated chitosan reduced mechanical performance. The cement showed good injectability and washout resistance. In vitro tests revealed increased cell proliferation in both DCPA and DCPA-p-chitosan. The cytocompatibility of the composite was comparable to hydroxyapatite. The mechanical and biological results suggest the composite is promising. The 5 wt % p-chitosan formulation outperformed other tested ratios.

The study demonstrated that 5 wt % p-chitosan improves the mechanical and biological properties of monetite cement. The composite showed good injectability and washout resistance. The compressive strength nearly doubled compared to pure monetite. The cytocompatibility was as high as that of hydroxyapatite. The researchers propose that this composite could serve as a bone repair material. The results suggest the material supports cell proliferation effectively. The optimal ratio of p-chitosan was identified as 5 wt %. The authors suggest that the composite offers a viable alternative to conventional cements.